Abstract: Glioblastomas are a subtype of gliomas, which are the most aggressive and deadly form of brain tumours. The epidermal growth factor receptor (EGFR) is over-expressed and amplified in glioblastomas. Luteolin is a common bioflavonoid found in a variety of fruits and vegetables. The aim of this study was to explore the molecular and biological effects of luteolin on EGF-induced cell proliferation and the potential of luteolin to induce apoptosis in glioblastoma cells. In vitro cell viability assays demonstrated that luteolin decreased cell proliferation in the presence or absence of EGF. Immunoblots revealed that luteolin decreased the protein expression levels of phosphorylated Akt, mTOR, p70S6K and MAPK in the presence of EGF. Furthermore, our results revealed the ability of luteolin to induce caspase and PARP cleavages in glioblastoma cells in addition to promoting cell cycle arrest. Our results demonstrated that luteolin has an inhibitory effect on downstream signalling molecules activated by EGFR, particularly the Akt and MAPK signalling pathways, and provided a rationale for further clinical investigation into the use of luteolin as a therapeutic molecule in the management of glioblastoma.
Of all the cancers originating in the central nervous system, malignant gliomas are the most common and are highly invasive. Glioblastoma multiforme (GBM) is both the most biologically aggressive and common of these gliomas [1, 2] . Glioblastoma represents over 80% of malignant gliomas [3] . GBM presents with uncontrolled cellular proliferation, diffuse infiltration, resistance to apoptosis, genomic instability and a tendency for necrosis. Characteristically, GBM manifests with heterogeneity at the histologic and genetic levels, contributing even further to the complexity of the disease. Due to this complexity and aggressiveness, GBM offers a therapeutic challenge, and a diverse treatment approach is necessary. Currently, treatment involves surgical resection, radiation and chemotherapy. Still, even with diverse treatment approaches, prognosis remains poor. The median survival is generally less than two years from diagnosis. Thus, further treatment options to improve this prognosis are necessary [2, 4] .
Epidermal growth factor receptor (EGFR) signalling plays an important role in many cancers including glioblastoma. EGFR, a member of the ErbB family of receptor tyrosine kinases (RTK), regulates the activation of the RTK/RAS/PI(3) K pathway. The activation of these pathways regulates key biological processes such as cell proliferation, angiogenesis, invasion and resistance to programmed cell death. Mutations such as the loss of phosphatase and tensin homologue (PTEN), an inhibitor of this pathway, are common in gliomas resulting in up-regulation of the pathway and resistance to EGFR therapies [5, 6] . In a genomic study of GBM, RTK alterations were found to occur in 67.3% of GBM, while EGFR mutations were found in 57.4% of these tumours. Additionally, these EGFR mutations were associated with significant elevations in total EGFR and its phosphorylation [7] . Due to the prevalence of these mutations, treatment options that can inhibit EGFR-mediated cell survival are needed.
Luteolin is a common flavonoid ( fig. 1 ), a class of secondary plant metabolites, found in a variety of fruits and vegetables. This class of compounds has demonstrated promising characteristics within the realm of cancer prevention and treatment. Flavonoids exhibit antioxidant properties, oestrogenic and anti-oestrogenic activity and antiproliferative ability. They have also been shown to induce detoxification enzymes, cell cycle arrest and the immune system [8, 9] . Additionally, some evidence points to a link between dietary flavonoids and reduced cancer risk [10] . Due to these properties, interest in these compounds as potential therapeutic agents for cancer treatment has continued to grow.
Along with its antioxidant and anti-inflammatory properties, luteolin has demonstrated anticancer effects in a variety of types of cancer through several mechanisms including inducing cell death, slowing cell proliferation and halting cell growth. Several studies have shown that luteolin down-regulates Akt phosphorylation in gastric, breast, brain and other cancer cell lines [11] [12] [13] [14] [15] [16] .
Although the effects of luteolin have been reported in a number of cancer cell lines including GBM, detailed molecular studies of its effects on EGFR-mediated signalling in GBM cells are lacking. We have been suggested that luteolin could attenuate EGFR-mediated cell proliferation and signalling in GBM. Our findings indicated that luteolin decreases EGF-induced cell proliferation and down-regulates downstream targets, such as phosphorylated MAPK and Akt, mediated by EGFR activation. In addition, we also observed that luteolin decreases the expression levels of Bcl-xL and induces both PARP and caspase cleavages.
Materials and Methods
Materials. Luteolin was obtained from Indofine Chemical Company (Hillsborough, NJ, USA). Luteolin was dissolved in DMSO and then diluted with the growth medium to the final concentrations. The antibodies targeting phosphorylated ERK, mTOR, p70S6K, Akt, caspase and Bcl-xL were obtained from Cell Signaling Technologies (Danvers, MA, USA). Secondary antibodies were purchased from Jackson Immuno-Research Laboratory (West Grove, PA, USA). EGF, PARP and caspase antibodies were obtained from R and D Biosystems (Minneapolis, MN, USA). The caspase inhibitor, Ac-DEVD-CHO, was obtained from Cayman Chemical (Ann Arbor, MI, USA). MTT cell proliferation kits were obtained from Promega (Madison, WI, USA). 0.4% Trypan blue was purchased from Gibco Life Technologies (Grand Island, NY, USA). Propidium iodide, Hoechst 33342, Triton X-100 and RNAse A were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture. Human glioblastoma cell lines U-87 MG and U-251 MG were obtained from Dr. Isa Hussaini, Department of Pathology, University of Virginia, Charlottesville, VA, USA. These cells were routinely maintained and cultured in alpha-MEM supplemented with 10% foetal bovine serum (FBS) obtained from Biowest, (Riverside, MO, USA), and 1% penicillin and streptomycin (Fisher Scientific, Pittsburg, PA, USA). Cells were incubated at 37°C in a 5% humidified incubator.
Cell transfection. Small interfering RNA (siRNA) was transfected into glioma cells as previously described by Amos et al. [17, 18] . The 'Smart pool' siRNA targeting the EGFR and the control siRNA were purchased from Dharmacon (Lafayette, CO, USA). The targeting sequences to EGFR are as follows:
J-003114-10: CAAAGUGUGUAACGGAAUA J-003114-11: CCAUAAAUGCUACGAAUAU J-003114-12: GUAACAAGCUCACGCAGUU J-003114-13: CAGAGGAUGUUCAAUAACU The transfection of these smart pool sequences into glioma cells was done according to the manufacturer's protocol for 48 hr. The cells were harvested and subjected to SDS-PAGE to detect the levels of EGFR.
Cell viability studies. Glioblastoma cells were cultured at a density of 1 x10
5 cells per well in 6-well plates, treated with various concentrations of luteolin (0-80 lM), and then incubated for one, two and three days. One hundred microlitres of cell suspensions was obtained from these plates and counted using a haemocytometer after adding 100 lL of trypan blue dye. These experiments were performed in triplicate.
The growth inhibitory effects of luteolin were evaluated in U-87 MG and U-251 MG glioblastoma cell lines using the MTT assay. This assay evaluates the ability of cells to metabolize a yellow tetrazolium salt to a formazan product. The formation of the purple formazan can be detected using a spectrophotometer. GBM cells were seeded in a 96-well plate at a density of 5.0 9 10 3 cells in 100 lL of media. After a 24-hr incubation period, GBM cells were treated with various concentrations of luteolin (0-80 lM) for 24, 48 and 72 hr. In another set of studies, GBM cells were treated with EGF (25 lg/mL) in the absence or presence of various concentrations of luteolin. Following treatments, 20 lL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well, and cells were incubated for 4 hr at 37°C. After the 4-hr incubation period, the stop reagent was added to each well according to the manufacturer's protocol. Plates were then rocked for 30 min. in the dark at room temperature. Cellular proliferation was determined by measuring the optical density using Promega Glomax Multidetection System (Madison, WI, USA). The mean AE S.E.M. for each experiment was calculated and plotted as a bar graph.
Cell cycle analysis by flow cytometry. U-87 MG cells were plated in 10-cm plates. Cells were serum starved and treated with varying concentrations of luteolin (0-80 lM) for 48 hr. After the 48-hr treatment, the floating cells were collected and adherent cells were trypsinized, pooled together and centrifuged at 800 9 g. Cell pellets were washed three times with PBS, fixed in ice-cold 70% ethanol and stored at 4°C overnight. The fixed cells were centrifuged and washed three times with PBS, and stained with a solution consisting of PBS with 20 lg/mL of propidium iodide, 0.1% Triton X-100 and 200 lg/ mL RNAse A. The cells were then kept in the dark for 1 hr. The stained cells were analysed using the BD FACScalibur equipped with CellQuest software. Cells were gated using the CellQuest software to estimate the proportion of cells distributed as a percentage in the different cell cycle compartments [19] .
Apoptotic cell staining. This assay allows for the detection of cells undergoing apoptosis. In this assay, GBM cells were cultured in a 12-well plate. Cells from each cell line were seeded at a density of 5 9 10 3 cells per well in 2 mL of media supplemented with 10% FBS. After 24 hr of incubation, the cells were treated with various concentrations of luteolin. After 48 hr, cells were washed three times with PBS and stained with 5 lg of Hoechst 33342 dye and 1 lg of propidium iodide dye. Plates were then left in the dark for 5 min. before photomicrographs of the cells were taken at a magnification of 109 under a fluorescent phase-contrast NIKON H600L Eclipse (Tokyo, Japan) microscope.
Western blot analysis. Western blot analyses were carried out as previously described by Amos et al. [17] . Cells were seeded in 6-well plates at a concentration of 1 9 10 5 cells/mL in a humidified atmosphere at 37°C for 24 hr. Following treatment with various concentrations of luteolin, cell lysates were prepared by lysing the cells in 1X lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na 2 EDTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM Na 3 VO 4 , 1 lg/mL leupeptin, 1 mM PMSF). Cell extracts were then EFFECTS OF LUTEOLIN ON GLIOBLASTOMA CELL PROLIFERATION spun at 16,000 g at 4°C for 10 min. Supernatants were then transferred to new tubes either for immediate analysis or storage at À80°C. Protein concentrations were quantified using a BCA TM Protein Assay Kit Thermo Fisher (Westminster, MD, USA). After protein quantification, the cell extracts were treated with sample buffer and boiled at 100°C for 5 min. Equivalent amounts of protein (20 lg) were loaded on a 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Following electrophoresis, gels were transferred onto nitrocellulose membranes. Nitrocellulose membranes were blocked in 1% Blotto (non-fat dry milk) for 1 hr followed by the addition of a diluted solution of the primary antibody against ERK1/2, Akt, mTOR or P70S6K. The membranes with the antibody solution were rocked at 4°C overnight. The membranes were then washed three times with PBST. Next, the membranes were treated with the appropriate peroxidase-conjugated secondary antibody (anti-mouse IgG or anti-rabbit IgG) for 1 hr. The membrane was washed three times with the wash buffer (PBST). Blots were then visualized using the enhanced chemiluminescence (ECL) reagents from Fisher Scientific (Milwaukee, WI, USA) as described by the manufacturer.
In sets of studies investigating the effects of PARP and caspase cleavage, glioma cell lines were treated with different concentrations of luteolin. Adherent and floating cells were pooled together and centrifuged at 800 9 g. The cell pellet was extracted with RIPA buffer and sonicated. The cell lysate was then centrifuged at 14,000 9 g for 10 min. at 4°C. Proteins (20 lg/lane) were separated by SDS-PAGE on 12% polyacrylamide gels, transferred onto nitrocellulose and then incubated with antibodies directed against PARP and caspase. Experiments were repeated three times for reproducibility. Densitometry and ImageQuant analysis were carried out using the Alpha Innotech FluorChem2 (Cell Biosciences, Santa Clara, CA, USA).
Statistical analysis. Data are expressed as the mean AE S.E.M. All statistical analyses were performed with the GraphPad Prism 7 software (La Jolla, CA, USA) using the one-way analysis of variance (ANOVA) followed by the Bonferroni test. A value of p < 0.05 was considered to be statistically significant.
Results
Effects of luteolin on cell growth and viability. To determine the effect of luteolin on glioblastoma cell growth and proliferation, GBM cell lines (U-87 MG and U- 251 MG) were used. We examined the rate of growth inhibition in cells treated with luteolin at (0-80 lM) using the trypan blue exclusion assay. This assay is based on the principle that live cells possess intact cell membranes and will exclude trypan blue, while dying cells possess compromised cell membranes and thus lack the ability to exclude the dye. We observed that both U-87 MG and U-251 MG treated with luteolin (0-80 lM) showed a dose-and time-dependent increase in trypan blue positivity ( fig. 2A,B ) compared with cells treated with control medium. Cell number was measured as a percentage of the control.
Furthermore, the viability of glioblastoma cells treated with luteolin was assessed using an MTT assay after treatment with luteolin (0-80 lM) for 24, 48 and 72 hr. This test assesses the ability of the cells to induce the metabolic conversion of a yellow tetrazolium salt to a formazan product. This conversion is considered as a measure of cell viability. Cells treated with luteolin (0-80 lM) alone for 24-72 hr showed a concentration and time-dependent decrease in cell proliferation ( fig. 2C,D) . In addition, we tested the possible inhibitory effects of luteolin on EGF-mediated increase in cell proliferation. In this study, GBM cells were pre-treated with varying concentrations of luteolin and then treated with EGF (25 ng/mL) for 24 hr. The increase or decrease in cell proliferation was measured, after the addition of the MTT dye, using a Promega Glomax Multidetection System spectrophotometer. Measurements were net changes from a baseline absorbance of 560 nm of control versus treated cells ( fig. 2E,F) .
Effects of luteolin on the signalling cascade.
We observed that luteolin induced a decrease in cell proliferation mediated by EGFR activation. Firstly, we established that treatment with EGF (25 ng/mL) induced a robust phosphorylation of the EGFR (Y845). We observed that at a 60-min. time-point, the phosphorylation was reduced (fig. 3A) . Furthermore, we transfected GBM cells with the siRNA targeting EGFR. Our results revealed that siRNA-treated cells down-regulate the expression of EGFR compared with the control non-targeting siRNA. Our data in fig. 3B indicate that the siRNA targeting EGFR knocked down the expression of EGFR, while treatment with luteolin (40 lM) did not decrease the expression of EGFR. Similarly, the phosphorylation of EGFR (Y845) was down-regulated in the presence of the siRNA targeting EGFR ( fig. 3C ) and the silencing of the EGFR abrogated EGF-mediated phosphorylation of the EGFR (Y845; fig. 3D ).
Thus, we decided to investigate the effects of luteolin on some downstream molecular targets mediated by EGFR activation such as MAPK, Akt, mTOR and S6K. We used Western blot analyses to determine changes in the protein levels of these signalling molecules. To do this, U-87 MG and U-251 MG glioma cell lines were treated with various concentrations of luteolin as well as 25 ng/mL EGF. Our data demonstrated a decrease in p-Akt and pERK ½ in a dose-dependent manner, in the presence of EGF ( fig. 4A,B) . Additionally, the phosphorylated levels of p-mTOR and p-p70S6K were also shown to decrease in a similar dose-dependent manner in the presence of EGF treatment ( fig. 4C,D) . This suggests that luteolin might be mediating decrease in cell proliferation and growth via attenuating key signalling molecules such as Akt and MAPK.
Effects of luteolin on apoptotic signalling. Western blot analysis was used to assess the effects of various concentrations of luteolin on the apoptotic signalling cascade induced by luteolin in glioma cells. The BCL-2 family plays a vital role in regulating apoptosis and the activation of the caspase cascade leading to PARP cleavage. In this study, the protein expression levels of Bcl-xL, caspase-3 and PARP were determined. We observed an increase in the levels of cleaved caspase and PARP with increasing concentrations of luteolin ( fig. 5A,B) . Furthermore, our data in fig. 5C revealed that Bcl-xL, an anti-apoptotic protein, was decreased in a dosedependent manner in both cell lines tested. To further explore the role of caspase-mediated PARP cleavage following luteolin treatment, cells were pre-treated with the caspase inhibitor Ac-DEVD-CHO and then treated with luteolin for 48 hr. Cell extracts were subjected to Western blot analysis, and we observed that pre-treatment with the caspase inhibitor inhibited cleavage of both PARP and caspase ( fig. 5D ). Additionally, we further determined the biological relevance of the inhibition with the caspase inhibitor by measuring the cell number using the trypan blue exclusion assay. After treatment with both the caspase inhibitor and luteolin, we observed no statistical difference in the cell number ( fig. 5E ).
Detection of apoptotic cells and cell cycle analysis.
To further investigate the molecular mechanisms underlying the effects of luteolin in GBM cell cycle checkpoints, we employed the technique of fluorescent activated cell sorting (FACS) to determine where in the cell cycle the cells are arrested. Analysis of the flow cytometric data revealed that luteolin potently increased the percentage of cells arrested in the S and G2M cell cycle checkpoints ( fig. 6A ). Our data showed that in the S phase ( fig. 6A lower panel), 8 .92% of control cells were arrested, while cells treated with luteolin (10-80 lM) had an increase in arrested cells from 18.83% (10 lM luteolin) to 38.8% (80 lM luteolin). In the G2M phase ( fig. 6A lower panel) , there was an increase in arrested cells from 6.5% (10 lM) to 20.2% (80 lM). Additionally, we observed a concentration-dependent increase in propidium iodide staining of cells treated with luteolin ( fig. 6B ).
Discussion
Glioblastoma multiforme is the most lethal of the malignant gliomas. As of yet, few therapeutic treatments have been suggested for GBM due to its heterogeneity and resistance to chemotherapy and radiotherapy. As a result, the long-term prognosis for GBM is often poor. Luteolin is a common flavonoid found in several dietary sources including celery, red and green peppers, thyme, and a variety of other spices. Luteolin's anticancer activity has been established in a variety of cancer cell lines such as breast, gastric, prostate, osteosarcoma and leukaemia among others [11, 12, [20] [21] [22] . Due to its previously established efficacy in several cancer cell lines, the authors of the present study sought to determine biological effects of luteolin EGFR-mediated signalling in glioblastoma multiforme U-87 and U-251 MG cells.
Our data revealed that luteolin induced apoptosis, inhibited proliferation and attenuated the effects of EGFR activation in U-87 MG and U-251 MG cells. Glioblastoma cells often have mutations leading to PARP and EGFR over-expression, which causes apoptotic resistance and uncontrolled cell growth.
Akt regulates a number of several cell survival, growth and proliferation pathways. Additionally, modulations in the Akt pathway play a significant role in many types of cancers. Akt over-expression is common in cancer, thus making this protein an important target for cancer treatment [23] . We observed that luteolin also decreased p-Akt levels in these glioma cell lines. Additionally, mutations resulting in ERK over-expression are also common in cancers. The ERK signalling pathway is known for its role in cell proliferation. It has also been shown to be involved in regulating other key biological processes, such as cellular differentiation and migration [24] . Our studies demonstrate the ability of luteolin to decrease p-ERK in cancer cell lines leading to decreased cell proliferation and growth. The combination of decreased MAPK and Akt could be responsible for the observed decreased in cell proliferation and survival [23] .
Epidermal growth factor, a ligand of the EGFR, is known to stimulate cell growth and proliferation. EGFR is overexpressed and amplified in glioblastoma as well as other types of cancers [1, 5] . As such, understanding the effects of luteolin on EGF activity provides a crucial look into the potential benefits of this compound. We found that luteolin inhibited cell growth and proliferation in the presence of cells pre-treated with EGF. Cells treated with luteolin were able to combat the effects of EGF, leading to more regulated growth and proliferation, and allowing for the activation of apoptosis. These observations agree with the findings of Lee et al. [12] and Hong et al. [25] which showed that luteolin decreased the EGFR mRNA in breast cancer via the inhibition of MAPK and suppression of the mTOR and Akt signalling pathways.
Luteolin has also demonstrated apoptotic effects by regulating and modifying the expression levels of proteins within the BCL-2 family. Because this family of proteins sets the threshold for apoptosis, a balance between various proteins within the family becomes important for cellular regulation and growth. In cancer, the pro-survival BCL-2 gene is often overexpressed. This prevents apoptosis, which aids the characteristics of uncontrolled growth and proliferation seen in cancer [26] . Our data showed that luteolin reduced expression of the pro-survival protein Bcl-xL similar to the findings by Wang et al. [21] , Tsai et al. [27] and Chang et al. [28] . The BCL activates certain caspases, which play a key role in regulating apoptosis. As a family, caspase proteins provide tumour suppression. Much like with the BCL family, mutations within the genes coding for the caspase proteins are common in cancers. Through these mutations, tumour suppression is inhibited. Our data also demonstrated the potential of luteolin to increase activated caspases in two different GBM cell lines. Cleavage and activation of caspases indicates an increase in apoptosis [20, 29] . Certain caspases are also involved in the regulation of PARP, which acts as a major DNA repair mechanism. In certain mutations, this repair mechanism is intensified yielding resistance to apoptosis. Our results revealed that luteolin induced PARP cleavage similar to the findings of Lim et al. [30] and the use of a caspase inhibitor abrogated its potential to cause PARP cleavage. Luteolin has shown promise in increasing cleaved PARP in cancer cell lines. Cleaved PARP loses its DNA repair mechanism, without which cells more freely undergo apoptosis. Thus, PARP inhibitors are a promising and growing avenue for cancer therapy [31, 32] . These data demonstrate luteolin's capacity to initiate the process of programmed cell death through the caspase family and inhibit pro-survival DNA repair through the modulation of PARP.
Collectively, our results demonstrate that luteolin decreases EGF-induced cell proliferation and some key signalling proteins such as Akt and MAPK. Luteolin also induces apoptosis as demonstrated by cleaved PARP and caspase. Given luteolin's biological activity, this agent deserves to be further explored for the treatment of GBM.
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